Clinical trials: Varicella Zoster Vaccine
Respiratory Disorders
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01. The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered…
- Trial name
- NCT03894969
- Testing
- GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E, Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
- Where
- 14 sites in Estonia, Finland and 3 more
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Japanese Encephalitis, Chickenpox
Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine
The purpose of this study is to observe the occurrence of adverse events and seroconversion rate, geometric mean titres (GMTs) of live attenuated varicella vaccine，live attenuated JE vaccine and live attenuated varicella vaccine…
- Trial name
- NCT01815073
- Testing
- Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine, Live Attenuated Varicella Vaccine, live attenuated JE vaccine
- Where
- China
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- Changchun Keygen Biological Products Co., Ltd.
Herpes Zoster
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
The purpose of the current ZOSTER-101 long-term follow-up (LTFU) study of ZOSTER-049 (NCT02723773) study, an extension of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies, is to assess the long-term vaccine…
- Trial name
- NCT05371080
- Testing
- HZ/su vaccine
- Where
- 107 sites in United States, Australia and 16 more
- Volunteers
- 3,038 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study
The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status.
- Trial name
- NCT01213810
- Testing
- Zostavax
- Sponsor
- University of Zurich
Varicella, Measles
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Primary Objective: To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles…
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432042
- Testing
- ProQuad®, Infanrix® hexa
- Where
- 50 sites in Germany, Italy
- Volunteers
- 955 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.
- Trial name
- NCT02581410
- Testing
- GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
- Where
- 32 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
- Trial name
- NCT06654700
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation
The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patient aged over 50 with history of hematopoietic stem cell…
- Trial name
- NCT03192319
- Testing
- Zostavax
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Seoul National University Hospital
Herpes Zoster, Pneumococcal Infection
ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)
The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are…
- Trial name
- NCT00535730
- Testing
- Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™, Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.
- Trial name
- NCT00550745
- Testing
- Zoster Vaccine, Live
- Volunteers
- 11,999 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Herpes Zoster-related Complications
A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
This study will evaluate the safety and immunogenicity of a heat-treated VZV vaccine in autologous or allogeneic hematopoietic cell transplant (HCT) recipients, human immunodeficiency virus (HIV)-infected participants with a…
- Trial name
- NCT00535236
- Testing
- V212
- Volunteers
- 341 people
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster Disease
Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates
Despite the significant benefits of herpes zoster vaccine (HZV), vaccination rates remain low. Electronic medical records (EMR) can serve as a practical strategy to better facilitate the application of preventative health care…
- Trial name
- NCT01519570
- Testing
- An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
- Where
- United States
- Volunteers
- 2,589 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Varicella, Influenza Vaccine
Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and trivalent inactivated influenza vaccine (TIV hereafter).
- Trial name
- NCT06987942
- Testing
- Varicella vaccine+TIV, Varicella vaccine, TIV
- Where
- China
- Volunteers
- 899 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster, HIV Infections
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Herpes zoster, or shingles, is the result of a viral infection that causes a painful skin rash, usually in older people or people with suppressed immune systems like those infected with HIV.
- Trial name
- NCT00851786
- Testing
- ZOSTAVAX
- Where
- 43 sites in United States
- Volunteers
- 395 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Varicella-zoster Virus
Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of 2 injections (approximately 2 months apart) of three different dose levels of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07285265
- Testing
- ABO1108, SHINGRIX
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an…
- Trial name
- NCT06740630
- Testing
- Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3
- Where
- 97 sites in United States, Belgium and 9 more
- Volunteers
- 1,840 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 50 years.
- Trial name
- NCT01165177
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 274 sites in United States, Australia and 16 more
- Volunteers
- 16,165 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mumps, Varicella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Varicella, Rubella, Measles
- Trial name
- NCT00127023
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 85 sites in Germany
- Volunteers
- 944 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older.
- Trial name
- NCT01610414
- Testing
- Herpes Zoster vaccine GSK1437173A
- Where
- 178 sites in United States, Australia and 26 more
- Volunteers
- 1,877 people
- Sponsor
- GlaxoSmithKline
Varicella
Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus
This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of…
- Trial name
- NCT05460429
- Testing
- Live attenuated varicella vaccine
- Where
- 3 sites in China
- Volunteers
- 37,920 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.